Cindy Serdjebi1, Florine Chandes1, Bastien Lepoivre1, Susanne E. Pors2, Michael Feigh2
1Biocellvia, Marseille, France 2Gubra A/S, Hørsholm, Denmark

Cindy Serdjebi, R&D Director,

Non-alcoholic steatohepatitis (NASH) predisposes to development of advanced fibrosis/cirrhosis. Many clinical trials are ongoing to obtain either significant resolution of NASH without worsening of fibrosis or improvement of fibrosis without worsening of NASH. Semaglutide (glucagon-like-receptor (GLP)-1 agonist) and lanifibranor (pan-peroxisome proliferator activated receptor agonist) are currently in late-stage clinical testing. The present study aimed at investigating the effects of these two monotherapies in the Gubra’s amylin NASH (GAN) diet-induced obese (DIO) and biopsy-confirmed mouse model using morphometric digital pathology.